关注
Miranda (Cheney) Perry
Miranda (Cheney) Perry
在 abbvie.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Polymorphs, salts, and cocrystals: what’s in a name?
S Aitipamula, R Banerjee, AK Bansal, K Biradha, ML Cheney, ...
Crystal growth & design 12 (5), 2147-2152, 2012
10562012
Pharmaceutical cocrystals: along the path to improved medicines
NK Duggirala, ML Perry, Ö Almarsson, MJ Zaworotko
Chemical communications 52 (4), 640-655, 2016
9292016
Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics
ML Cheney, DR Weyna, N Shan, M Hanna, L Wojtas, MJ Zaworotko
Journal of pharmaceutical sciences 100 (6), 2172-2181, 2011
2732011
Effects of crystal form on solubility and pharmacokinetics: a crystal engineering case study of lamotrigine
ML Cheney, N Shan, ER Healey, M Hanna, L Wojtas, MJ Zaworotko, ...
Crystal Growth & Design 10 (1), 394-405, 2010
2732010
Supramolecular architectures of meloxicam carboxylic acid cocrystals, a crystal engineering case study
ML Cheney, DR Weyna, N Shan, M Hanna, L Wojtas, MJ Zaworotko
Crystal growth & design 10 (10), 4401-4413, 2010
1482010
Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics
N Shan, ML Perry, DR Weyna, MJ Zaworotko
Expert opinion on drug metabolism & toxicology 10 (9), 1255-1271, 2014
1442014
Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation
DR Weyna, ML Cheney, N Shan, M Hanna, MJ Zaworotko, V Sava, ...
Molecular pharmaceutics 9 (7), 2094-2102, 2012
1442012
Crystallization method and bioavailability
M Hanna, N Shan, M Cheney, D Weyna, RK Houck
US Patent 8,399,023, 2013
1172013
Oral forms of a phosphonic acid derivative
M Hanna, N Shan, M Cheney, D Weyna
US Patent 8,980,868, 2015
1092015
In vivo studies of crystalline forms of meloxicam
M Hanna, N Shan, ML Cheney, DR Weyna
US Patent 8,124,603, 2012
982012
The role of cocrystals in solid-state synthesis: cocrystal-controlled solid-state synthesis of imides
ML Cheney, GJ McManus, JA Perman, Z Wang, MJ Zaworotko
Crystal growth & design 7 (4), 616-617, 2007
962007
Crystallization method and bioavailability
M Hanna, N Shan, ML Cheney, DR Weyna, RK Houck
US Patent 8,933,057, 2015
892015
Crystallization method and bioavailability
M Hanna, N Shan, ML Cheney, DR Weyna, R Houck
US Patent 9,169,279, 2015
852015
Hydrogen bond hierarchy: persistent phenol··· chloride hydrogen bonds in the presence of carboxylic acid moieties
NK Duggirala, GPF Wood, A Fischer, Ł Wojtas, ML Perry, MJ Zaworotko
Crystal Growth & Design 15 (9), 4341-4354, 2015
612015
Towards an understanding of the propensity for crystalline hydrate formation by molecular compounds
A Bajpai, HS Scott, T Pham, KJ Chen, B Space, M Lusi, ML Perry, ...
IUCrJ 3 (6), 430-439, 2016
502016
Improving biopharmaceutical properties of vinpocetine through cocrystallization
S Golob, M Perry, M Lusi, MR Chierotti, I Grabnar, L Lassiani, D Voinovich, ...
Journal of pharmaceutical sciences 105 (12), 3626-3633, 2016
422016
Crystal engineering of multiple-component organic solids: Pharmaceutical cocrystals of tadalafil with persistent hydrogen bonding motifs
DR Weyna, ML Cheney, N Shan, M Hanna, Ł Wojtas, MJ Zaworotko
CrystEngComm 14 (7), 2377-2380, 2012
402012
Cocrystal Controlled Solid-State Synthesis. A Green Chemistry Experiment for Undergraduate Organic Chemistry
ML Cheney, MJ Zaworotko, S Beaton, RD Singer
Journal of chemical education 85 (12), 1649, 2008
342008
Cocrystal Polymorphs and Solvates of the Anti-Trypanosoma cruzi Drug Benznidazole with Improved Dissolution Performance
BP Bezerra, D Pogoda, ML Perry, LMT Vidal, MJ Zaworotko, AP Ayala
Crystal Growth & Design 20 (7), 4707-4718, 2020
232020
Chloral hydrate polymorphs and cocrystal revisited: solving two pharmaceutical cold cases
D O’Nolan, ML Perry, MJ Zaworotko
Crystal Growth & Design 16 (4), 2211-2217, 2016
222016
系统目前无法执行此操作,请稍后再试。
文章 1–20